The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09
- PDF / 180,959 Bytes
- 2 Pages / 595.276 x 793.701 pts Page_size
- 54 Downloads / 164 Views
EDITORIAL
Open Access
The “Excellence in Translational Medicine” and “Bedside-to-Bench” Awards 2008-09 Richard J Ablin1*, Francesco M Marincola2, Pier Giorgio Natali3
In a continuing endeavor to recognize outstanding contributions in the field of translational medicine, the Editorial Board of the Journal of Translational Medicine (JTM) established “The Excellence in Translational Medicine Award” in 2006 [1]. With the thought to also recognize excellent studies, defined as those exclusively based on the study of human subjects, the Editorial Board has further established “The Bedside-to-Bench Award” in 2008 [2]. The recipients of “The Excellence in Translational Medicine” and “Bedside-to-Bench” Awards will each receive a $5,000 prize sponsored by Medistem http:// www.medisteminc.com/ and the Harry J. Lloyd Fund, respectively. The funds received from each Award are to be used to cover expenses for any meeting sponsored by a non-for-profit organization that is relevant to the goal of translational medicine and research. Twenty-three papers nominated, including 13 highly accessed, from investigators representative of ten countries of five continents, covering a wide range of disciplines published in JTM between 1 July 2008-30 June 2009 were evaluated. For this purpose, an Award Committee* comprised of eight members of the Editorial Board selected and co-chaired by Richard J. Ablin (University of Arizona College of Medicine and the Arizona Cancer Center, Tucson, AZ) and Pier Giorgio Natali (CINBO Laboratories, “G.d’Annunzio” University, Chieti, Italy) was formed. The initial National Institutes of Health Scoring System of 1-5, with 1 = Outstanding and 5 = Poor, were used with the papers being evaluated with regard to their: • Scientific merit • Originality • Clarity
* Correspondence: [email protected] 1 Department of Pathology, University of Arizona College of Medicine; Arizona Cancer Center and BIO5 Institute, Tucson, AZ 85724, USA Full list of author information is available at the end of the article
• Relevance to the purposes of translational medicine and research (and in “The Bedside-to-Bench Award” to direct study of human subjects) • Research design • Methodology
Excellence in Translational Medicine Award In the paper by Hye-Won Chung [3], recipient of the “Excellence in Translational Medicine Award for 200809,” Doctor Chung and colleagues of Yonsei University College of Medicine (Seoul, Korea) and the NIH (Bethesda, MD) have demonstrated a correlation between the serum levels of high mobility group protein box-1 (HMGB1) and the clinical and pathological characteristics of patients with gastric cancer (GC) and its suggested role therein as a biomarker. Part of a group of chromosomal proteins known as the high mobility group (HMG) encoded by the HMBG1 gene, they are functionally involved in transcription, replication, recombination and DNA repair. HMGB1, a member of the HMG family of proteins, has been demonstrated to serve as a cytokine mediating lethal systemic inflammation via its extracellular re
Data Loading...
